Biohit Oyj (BIOBV.HE)
EUR 2.52
(-1.98%)
EUR 2.52
(-1.98%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.85 Million EUR | 207.99% |
| 2022 | 601 Thousand EUR | 140.07% |
| 2021 | -1.5 Million EUR | 54.71% |
| 2020 | -3.31 Million EUR | -133.9% |
| 2019 | -1.41 Million EUR | 33.92% |
| 2018 | -2.14 Million EUR | -134.91% |
| 2017 | 6.13 Million EUR | 286.31% |
| 2016 | -3.29 Million EUR | -12.96% |
| 2015 | -2.91 Million EUR | -151.25% |
| 2014 | -1.16 Million EUR | 80.38% |
| 2013 | -5.91 Million EUR | -61.84% |
| 2012 | -3.65 Million EUR | -109.7% |
| 2011 | 37.71 Million EUR | 61719.67% |
| 2010 | 61 Thousand EUR | -84.24% |
| 2009 | 387 Thousand EUR | -56.86% |
| 2008 | 897 Thousand EUR | 159.72% |
| 2007 | -1.5 Million EUR | -79.02% |
| 2006 | -839 Thousand EUR | -271.24% |
| 2005 | -226 Thousand EUR | -33.73% |
| 2004 | -169 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 600 Thousand EUR | 0.0% |
| 2024 Q1 | 600 Thousand EUR | 20.0% |
| 2023 FY | 1.85 Million EUR | 207.99% |
| 2023 Q1 | 700 Thousand EUR | 333.33% |
| 2023 Q2 | 1.4 Million EUR | 100.0% |
| 2023 Q3 | 225.5 Thousand EUR | -83.89% |
| 2023 Q4 | 500 Thousand EUR | 121.73% |
| 2022 Q3 | -149.5 Thousand EUR | -116.61% |
| 2022 Q1 | 450 Thousand EUR | 212.5% |
| 2022 FY | 601 Thousand EUR | 140.07% |
| 2022 Q4 | -300 Thousand EUR | -100.67% |
| 2022 Q2 | 900 Thousand EUR | 100.0% |
| 2021 FY | -1.5 Million EUR | 54.71% |
| 2021 Q4 | -400 Thousand EUR | -100.0% |
| 2021 Q1 | -550 Thousand EUR | 45.0% |
| 2021 Q3 | -200 Thousand EUR | 81.82% |
| 2021 Q2 | -1.1 Million EUR | -100.0% |
| 2020 Q3 | -506.49 Thousand EUR | 77.98% |
| 2020 FY | -3.31 Million EUR | -133.9% |
| 2020 Q2 | -2.3 Million EUR | -100.0% |
| 2020 Q1 | -1.15 Million EUR | -43.75% |
| 2020 Q4 | -1 Million EUR | -97.43% |
| 2019 Q3 | -408.5 Thousand EUR | 31.92% |
| 2019 Q4 | -800 Thousand EUR | -95.84% |
| 2019 FY | -1.41 Million EUR | 33.92% |
| 2019 Q2 | -600 Thousand EUR | -100.0% |
| 2019 Q1 | -300 Thousand EUR | 47.51% |
| 2018 FY | -2.14 Million EUR | -134.91% |
| 2018 Q3 | -571.5 Thousand EUR | -14.3% |
| 2018 Q2 | -500 Thousand EUR | 0.0% |
| 2018 Q1 | -500 Thousand EUR | 5.75% |
| 2018 Q4 | -571.5 Thousand EUR | 0.0% |
| 2017 Q3 | -530.5 Thousand EUR | -114.74% |
| 2017 Q1 | 3.6 Million EUR | 702.51% |
| 2017 Q4 | -530.5 Thousand EUR | 0.0% |
| 2017 FY | 6.13 Million EUR | 286.31% |
| 2017 Q2 | 3.6 Million EUR | 0.0% |
| 2016 Q3 | -597.5 Thousand EUR | 43.1% |
| 2016 Q1 | -1.05 Million EUR | 25.9% |
| 2016 FY | -3.29 Million EUR | -12.96% |
| 2016 Q4 | -597.5 Thousand EUR | 0.0% |
| 2016 Q2 | -1.05 Million EUR | 0.0% |
| 2015 Q3 | -100 Thousand EUR | 75.0% |
| 2015 Q2 | -400 Thousand EUR | 55.56% |
| 2015 Q1 | -900 Thousand EUR | 22.48% |
| 2015 Q4 | -1.41 Million EUR | -1317.0% |
| 2015 FY | -2.91 Million EUR | -151.25% |
| 2014 Q1 | 2.2 Million EUR | 236.05% |
| 2014 FY | -1.16 Million EUR | 80.38% |
| 2014 Q4 | -1.16 Million EUR | -29.0% |
| 2014 Q3 | -900 Thousand EUR | 30.77% |
| 2014 Q2 | -1.3 Million EUR | -159.09% |
| 2013 Q3 | -900 Thousand EUR | 64.0% |
| 2013 Q4 | -1.61 Million EUR | -79.67% |
| 2013 Q1 | -1 Million EUR | -16.82% |
| 2013 Q2 | -2.5 Million EUR | -150.0% |
| 2013 FY | -5.91 Million EUR | -61.84% |
| 2012 FY | -3.65 Million EUR | -109.7% |
| 2012 Q3 | -800 Thousand EUR | 33.33% |
| 2012 Q2 | -1.2 Million EUR | -33.33% |
| 2012 Q4 | -856 Thousand EUR | -7.0% |
| 2012 Q1 | -900 Thousand EUR | -102.41% |
| 2011 Q4 | 37.31 Million EUR | 9227.5% |
| 2011 Q1 | - EUR | 100.0% |
| 2011 Q2 | -100 Thousand EUR | 0.0% |
| 2011 Q3 | 400 Thousand EUR | 500.0% |
| 2011 FY | 37.71 Million EUR | 61719.67% |
| 2010 Q2 | 100 Thousand EUR | 0.0% |
| 2010 Q3 | -200 Thousand EUR | -300.0% |
| 2010 Q1 | 100 Thousand EUR | -82.96% |
| 2010 Q4 | -39 Thousand EUR | 80.5% |
| 2010 FY | 61 Thousand EUR | -84.24% |
| 2009 Q1 | -100 Thousand EUR | 0.0% |
| 2009 FY | 387 Thousand EUR | -56.86% |
| 2009 Q4 | 587 Thousand EUR | 393.5% |
| 2009 Q3 | -200 Thousand EUR | 0.0% |
| 2009 Q2 | - EUR | 100.0% |
| 2008 FY | 897 Thousand EUR | 159.72% |
| 2007 FY | -1.5 Million EUR | -79.02% |
| 2006 FY | -839 Thousand EUR | -271.24% |
| 2005 FY | -226 Thousand EUR | -33.73% |
| 2004 FY | -169 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Herantis Pharma Oyj | 279.84 Thousand EUR | -561.449% |
| Nanoform Finland Oyj | -20.75 Million EUR | 108.918% |